- Home
- YPF vs MRNA Comparison
YPF vs MRNA Comparison
Compare YPF & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YPF
- MRNA
- Stock Information
- Founded
- YPF 1977
- MRNA 2010
- Country
- YPF Argentina
- MRNA United States
- Employees
- YPF N/A
- MRNA N/A
- Industry
- YPF Integrated oil Companies
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YPF Energy
- MRNA Health Care
- Exchange
- YPF Nasdaq
- MRNA Nasdaq
- Market Cap
- YPF 16.8B
- MRNA 16.0B
- IPO Year
- YPF 1993
- MRNA 2018
- Fundamental
- Price
- YPF $39.32
- MRNA $34.17
- Analyst Decision
- YPF Buy
- MRNA Hold
- Analyst Count
- YPF 8
- MRNA 20
- Target Price
- YPF $37.64
- MRNA $67.06
- AVG Volume (30 Days)
- YPF 2.4M
- MRNA 13.0M
- Earning Date
- YPF 03-05-2025
- MRNA 02-14-2025
- Dividend Yield
- YPF N/A
- MRNA N/A
- EPS Growth
- YPF 426.45
- MRNA N/A
- EPS
- YPF 2.00
- MRNA N/A
- Revenue
- YPF $15,678,121,770.00
- MRNA $5,081,000,000.00
- Revenue This Year
- YPF $264.76
- MRNA N/A
- Revenue Next Year
- YPF N/A
- MRNA N/A
- P/E Ratio
- YPF $22.01
- MRNA N/A
- Revenue Growth
- YPF 269.29
- MRNA N/A
- 52 Week Low
- YPF $14.94
- MRNA $31.94
- 52 Week High
- YPF $47.43
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- YPF 40.86
- MRNA 38.80
- Support Level
- YPF $38.09
- MRNA $40.71
- Resistance Level
- YPF $41.18
- MRNA $45.15
- Average True Range (ATR)
- YPF 1.53
- MRNA 3.23
- MACD
- YPF -0.61
- MRNA -0.22
- Stochastic Oscillator
- YPF 17.72
- MRNA 6.88
About YPF YPF Sociedad Anonima
YPF SA is an Argentina-based integrated oil and gas company. It is engaged in operating a fully integrated oil and gas chain across the domestic upstream, downstream, and gas and power segments. The company's upstream operations consist of the exploration, development, and production of crude oil, natural gas, and LPG. Its downstream operations include the refining, marketing, transportation, and distribution of oil and a wide range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels. The company generates maximum revenue from the downstream segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.